Ir para o conteúdo principal

Bioventus (NYSE: BVS) — Perfil da empresa, notícias e dados financeiros

Logo de Bioventus
BVS Bioventus
Bioventus primary media
Perfil da empresa

Bioventus

Bioventus (NASDAQ:BVS) focuses on innovating and delivering products that help people heal and resume their active lifestyles. The company specializes in orthobiologics, surgical, and non-surgical therapies aimed at bone healing, bone graft, and knee osteoarthritis among other musculoskeletal conditions. With a strong commitment to high-quality clinical research, Bioventus aims to provide effective solutions that support the body’s natural healing processes. Their projects range from developing innovative treatment options to expanding their global reach to help more patients around the world. The objective of Bioventus is to improve the lives of people suffering from joint and musculoskeletal issues, driving forward with the goal of becoming a trusted leader in their specialized field.

Resumo

Public USParticipação acionária
2011Ano de fundação
970Funcionários
North Carolina, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Bioventus

  • EXOGEN Ultrasound Bone Healing System, a device that uses low-intensity pulsed ultrasound to stimulate bone healing.
  • DUROLANE, a single injection hyaluronic acid product for treating knee osteoarthritis pain.
  • GELSYN-3, a three-injection regimen for knee osteoarthritis, providing pain relief and improved function.
  • SUPARTZ FX, a series of injections intended to replace knee joint fluid, reducing osteoarthritis pain and improving mobility.
  • Bioventus Surgical, offering bone graft solutions like OSTEOAMP for spinal fusion surgeries, enhancing bone growth and healing.
  • SIGNAFUSE Bioactive Bone Graft, a product supporting bone repair by incorporating bioactive glass into a resorbable binder.

equipe executiva do Bioventus

  • Robert E. ClaypoolePresident, CEO & Director
  • Mark L. SingletonSenior VP & CFO
  • Anthony D'AdamioSenior VP, General Counsel & Corporate Secretary
  • Mike CroweSenior Vice President of Operations
  • David CrawfordVice President of Investor Relations & Treasurer
  • Katrina J. ChurchSenior VP & Chief Compliance Officer
  • Helen LeupoldSenior VP & Chief Human Resources Officer
  • Dave VennerSenior VP & GM of Surgical

Principais indicadores financeiros

Resultados divulgados pela Bioventus, em USD.

Cap. de mercado
985 mi
Receita (TTM)
581,8 mi
P/L
18.5
LPA (diluído, TTM)
0.8
Dividend yield
—
Margem de lucro
9.4%
Receita e lucro anuais da Bioventus
Fim do ano fiscalReceitaResultado operacionalLucro líquido
568,1 mi58,5 mi22,7 mi
573,3 mi-12 mi-33,5 mi
512,3 mi-81,7 mi-156,2 mi
512,1 mi-167,2 mi-158,7 mi